nivolumab extends survival for patients with the most common lung cancer
Published 9 years ago • 1K plays • Length 5:49Download video MP4
Download video MP3
Similar videos
-
8:29
asco 2015: nivolumab extends survival for patients with the most common lung cancer
-
8:21
nivolumab extends survival for patients with the most common lung cancer
-
8:23
nivolumab extends survival for nsclc
-
5:10
neoadjuvant nivolumab chemo continues to provide long-term clinical benefit for nsclc patients
-
6:03
checkmate 9la: nivolumab, ipilimumab and chemotherapy for stage iv nsclc
-
1:01
dr. heymach on nivolumab for lung cancer
-
6:04
checkmate 816 trial: nivolumab platinum-doublet chemotherapy vs chemo as neoadjuvant treatment...
-
0:39
phase i/ii study of adapt-001 plus an ici for patients with immune refractory cancers
-
3:14
comment: nivolumab plus ipilimumab combination for advanced nsclc
-
5:22
checkmate 743: first-line nivolumab plus ipilimumab vs chemotherapy in patients with unresectabl...
-
3:12
opdivo (nivolumab) the immunotherapy cancer treatment
-
0:39
dr. lopes on the fda approval of nivolumab/ipilimumab in nsclc
-
3:23
nivolumab improves overall survival for advanced kidney cancer
-
5:16
tumour shrinkage with ipilimumab plus nivolumab in patients with neuroendocrine carcinoma
-
3:59
checkmate 067 - combined nivolumab and ipilimumab
-
9:40
results: neoadjuvant nivolumab for resectable lung cancer
-
2:27
study finds neoadjuvant nivolumab to show long-term benefit in patients with nsclc
-
4:30
five-year follow-up of nivolumab in nsclc
-
6:20
response and safety profile of neoadjuvant nivolumab for resectable lung cancer